Inify Laboratories aktie (INIFY)

Inify Laboratories: Solid topline growth, strong UK development, and positive response to gastrointestinal diagnostics

Inify Laboratories: Stabil försäljningstillväxt, stark utveckling i Storbritannien och positiv respons på gastrointestinal diagnostik

Cision • 25 feb 08:00

Inify Laboratories announces final results of fully guaranteed private placement

Cision • 19 dec 2025 13:18

Inify Laboratories - mandatory notification of trade

Cision • 19 dec 2025 08:36

Inify Laboratories: Key information regarding Repair Issue

Cision • 17 dec 2025 08:15

Inify Laboratories announces preliminary results of fully guaranteed private placement

Cision • 17 dec 2025 08:00

Inify Laboratories - notification of trade

Cision • 16 dec 2025 14:11

Inify Laboratories announces application periods for fully guaranteed private placement and fully guaranteed repair issue

Cision • 09 dec 2025 08:00

Kommuniké från extra bolagsstämma i Inify Laboratories AB

Cision • 04 dec 2025 13:06

Bulletin from the extraordinary general meeting of Inify Laboratories AB

Cision • 04 dec 2025 13:06

Inify Laboratories: Board announces updated timetable for settlement in proposed Private Placement and Repair Issue

Cision • 03 dec 2025 13:30

Inify Laboratories - notice of Extraordinary General Meeting on December 4, 2025

Cision • 12 nov 2025 15:09

Inify Laboratories – kallelse till extra bolagsstämma 4 december 2025

Cision • 12 nov 2025 15:09

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

Cision • 12 nov 2025 10:50

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

Cision • 12 nov 2025 10:50

Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Cision • 29 okt 2025 11:15

Korrigering - Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien är på god väg mot öppning i början av 2026

Korrigering - Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien ä...

Cision • 29 okt 2025 11:15

Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Cision • 29 okt 2025 08:00

Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien är på god väg mot öppning i början av 2026

Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien är på god väg m...

Cision • 29 okt 2025 08:00

Inify Laboratories - mandatory notification of trade

Cision • 29 aug 2025 11:56

Inify Laboratories: Solid growth in Sweden and first patient diagnostics delivered in the UK

Cision • 27 aug 2025 08:00

Inify Laboratories: Stabil tillväxt i Sverige och första patientdiagnostiken levererad i Storbritannien

Cision • 27 aug 2025 08:00

Inify Laboratories AB (publ) – summary of Annual General Meeting

Cision • 21 maj 2025 08:00

Inify Laboratories AB (publ) – kommuniké från årsstämma

Cision • 21 maj 2025 08:00

Inify Laboratories: Continued strong growth – construction and establishment in the UK

Cision • 30 apr 2025 08:00

Inify Laboratories: Fortsatt stark tillväxt - uppbyggnad och etablering i Storbritannien

Cision • 30 apr 2025 08:00

Inify Laboratories - Årsredovisning 2024

Cision • 16 apr 2025 08:00

Inify Laboratories – notice of Annual General Meeting on May 20, 2025

Cision • 16 apr 2025 08:00

Inify Laboratories – kallelse till årsstämma den 20 maj 2025

Cision • 16 apr 2025 08:00

Inify Laboratories - Annual Report 2024

Cision • 16 apr 2025 08:00

Inify Laboratories: 60% försäljningstillväxt och mycket positiv respons på expansionen till Storbritannien

Cision • 26 feb 2025 08:00

Inify Laboratories: 60% quarterly sales growth and highly positive response to UK expansion

Cision • 26 feb 2025 08:00

Inify Laboratories – New share capital registered

Cision • 14 feb 2025 14:01

Inify Laboratories – Resolution to issue new shares in Private Placement and Subsequent Offering

Cision • 12 feb 2025 14:45

Inify Laboratories - mandatory notification of trade

Cision • 30 jan 2025 11:57

Inify Laboratories - mandatory notification of trade

Cision • 24 jan 2025 20:00

Inify Laboratories – Final results of the Subsequent Offering

Cision • 23 jan 2025 20:49

Inify Laboratories – Last day of the subscription period in the Subsequent Offering

Cision • 23 jan 2025 07:30

Inify Laboratories – Commencement of subscription period for Subsequent Offering

Cision • 09 jan 2025 07:30

Inify Laboratories enter into agreement with Swedish region

Cision • 08 jan 2025 11:31

Inify Laboratories ingår avtal med Region Västmanland

Cision • 08 jan 2025 11:31

Inify Laboratories – Registration of prospectus and upcoming launch of Subsequent Offering

Cision • 07 jan 2025 17:04

Inify Laboratories - mandatory notification of trade

Cision • 16 dec 2024 13:30

Inify Laboratories: Key information regarding potential Subsequent Offering

Cision • 16 dec 2024 08:05

Inify Laboratories announces successful placement of fully guaranteed private placement

Cision • 16 dec 2024 08:00

Inify Laboratories announces application periods for fully guaranteed private placement and fully guaranteed subsequent repair issue

Cision • 09 dec 2024 12:04

Inify Laboratories AB (publ) - Kommuniké från extra bolagsstämma

Cision • 06 dec 2024 12:00

Inify Laboratories AB (publ) - Bulletin from the extraordinary general meeting

Cision • 06 dec 2024 12:00

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of SEK 150 million

Cision • 15 nov 2024 12:00

Inify Laboratories - notice of Extraordinary General Meeting on December 6, 2024

Cision • 15 nov 2024 12:00

Inify Laboratories – kallelse till extra bolagsstämma 6 december 2024

Cision • 15 nov 2024 12:00

Inify Laboratories: Establishment in the United Kingdom and expansion into gastrointestinal diagnostics

Cision • 23 okt 2024 08:00

Inify Laboratories: Etablering i Storbritannien och expansion inom mag-tarmdiagnostik

Cision • 23 okt 2024 08:00

INIFY Laboratories: 62% revenue growth and strong international interest

Cision • 21 aug 2024 08:00

INIFY Laboratories: 62% omsättningstillväxt och starkt internationellt intresse

Cision • 21 aug 2024 08:00

Inify Laboratories AB (publ) – summary of Annual General Meeting

Cision • 15 maj 2024 08:00

Inify Laboratories AB (publ) – kommuniké från årsstämma

Cision • 15 maj 2024 08:00

Inify Laboratories - More diagnoses delivered in the first quarter than in the whole of 2023

Cision • 24 apr 2024 08:00

Inify Laboratories - Fler diagnoser levererade under första kvartalet än under hela 2023

Cision • 24 apr 2024 08:00

Inify Laboratories - Årsredovisning 2023

Cision • 11 apr 2024 08:00

Inify Laboratories – notice of Annual General Meeting on May 14, 2024

Cision • 11 apr 2024 08:00

Inify Laboratories – kallelse till årsstämma den 14 maj 2024

Cision • 11 apr 2024 08:00

Inify Laboratories - Annual Report 2023

Cision • 11 apr 2024 08:00

Förutser en märkbar ökning av kunder, volym och försäljning under 2024

Cision • 29 feb 2024 08:00

Foresees a noticeable increase of customers, volume, and sales in 2024

Cision • 29 feb 2024 08:00

Inify Laboratories erhåller ackreditering som medicinskt laboratorium

Cision • 06 nov 2023 09:00

Inify Laboratories receives accreditation as a medical laboratory

Cision • 06 nov 2023 09:00

Kontinuerlig diagnostikverksamhet och mycket positiv kundrespons

Cision • 24 okt 2023 08:00

Continuous diagnostic operation and very positive feedback from customers

Cision • 24 okt 2023 08:00

Inify Laboratories - Lyckad laboratorielansering under Q2 med leverans av första prostatacancerdiagnoserna

Cision • 23 aug 2023 08:00

Inify Laboratories - Successful laboratory launch in Q2 with delivery of first prostate cancer diagnosis

Cision • 23 aug 2023 08:00

Inify Laboratories - mandatory notification of trade

Cision • 05 jul 2023 15:41

Successful launch of Inify Laboratories’ services, with first patient cases diagnosed

Cision • 20 jun 2023 08:00

Framgångsrik lansering av Inify Laboratories tjänster – första patientfallen har diagnostiserats

Cision • 20 jun 2023 08:00

Inify Laboratories AB (publ) – kommuniké från årsstämma

Cision • 17 maj 2023 08:55

Inify Laboratories AB (publ) – summary of Annual General Meeting

Cision • 17 maj 2023 08:55

Inify Laboratories - Strong market interest and launch on track

Cision • 26 apr 2023 08:00

Inify Laboratories - Årsredovisning 2022

Cision • 12 apr 2023 08:00

Inify Laboratories - notice of Annual General Meeting on May 16, 2023

Cision • 12 apr 2023 08:00

Inify Laboratories - kallelse till årsstämma den 16 maj 2023

Cision • 12 apr 2023 08:00

Inify Laboratories - Annual Report 2022

Cision • 12 apr 2023 08:00

Panel talk about Inify's fourth quarter 2022

From the heart of their brand-new laboratory comes this panel talk with CEO Fredrik Palm and CTO Arto Järvinen of Inify Laboratories.

Cision • 23 feb 2023 16:18

Inify Laboratories - Ultramodern AI-based digital pathology laboratory completed in record time

Cision • 22 feb 2023 08:00

INIFY Laboratories - Laboratory and recruitment on track with positive market feedback

Cision • 26 okt 2022 08:00

Inify Laboratories AB (publ) – Extra bolagsstämma

Cision • 30 aug 2022 11:31

Inify Laboratories AB (publ) – Extraordinary General Meeting

Cision • 30 aug 2022 11:31

Inify Laboratories - mandatory notification of trade

Cision • 19 aug 2022 14:17

Inify’s first ultramodern laboratory on track

Cision • 17 aug 2022 08:00

Inify’s first ultramodern laboratory on track

Cision • 17 aug 2022 08:00

Notice to Extraordinary General Meeting in Inify Laboratories AB (publ)

Cision • 28 jul 2022 08:00

Kallelse till extra bolagsstämma i Inify Laboratories AB (publ)

Cision • 28 jul 2022 08:00

Pressmeddelanden från Inify Laboratories

Inify Laboratories: Solid topline growth, strong UK development, and positive response to gastrointestinal diagnostics

Inify Laboratories: Stabil försäljningstillväxt, stark utveckling i Storbritannien och positiv respons på gastrointestinal diagnostik

Correction: Inify Laboratories - mandatory notification of trade

Inify Laboratories - mandatory notification of trade

Inify Laboratories – Final Results of the Repair Issue

Inify Laboratories – Commencement of subscription period for Repair Issue

Inify Laboratories - mandatory notification of trade

Inify Laboratories announces final results of fully guaranteed private placement

Inify Laboratories - mandatory notification of trade

Inify Laboratories: Key information regarding Repair Issue

Inify Laboratories announces preliminary results of fully guaranteed private placement

Inify Laboratories - notification of trade

Inify Laboratories announces application periods for fully guaranteed private placement and fully guaranteed repair issue

Kommuniké från extra bolagsstämma i Inify Laboratories AB

Bulletin from the extraordinary general meeting of Inify Laboratories AB

Inify Laboratories: Board announces updated timetable for settlement in proposed Private Placement and Repair Issue

Inify Laboratories - notice of Extraordinary General Meeting on December 4, 2025

Inify Laboratories – kallelse till extra bolagsstämma 4 december 2025

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of NOK 100 million

Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Korrigering - Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien är på god väg mot öppning i början av 2026

Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026

Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien är på god väg mot öppning i början av 2026

Inify Laboratories - mandatory notification of trade

Inify Laboratories: Solid growth in Sweden and first patient diagnostics delivered in the UK

Inify Laboratories: Stabil tillväxt i Sverige och första patientdiagnostiken levererad i Storbritannien

Inify Laboratories AB (publ) – summary of Annual General Meeting

Inify Laboratories AB (publ) – kommuniké från årsstämma

Inify Laboratories: Continued strong growth – construction and establishment in the UK

Inify Laboratories: Fortsatt stark tillväxt - uppbyggnad och etablering i Storbritannien

Inify Laboratories - Årsredovisning 2024

Inify Laboratories – notice of Annual General Meeting on May 20, 2025

Inify Laboratories – kallelse till årsstämma den 20 maj 2025

Inify Laboratories - Annual Report 2024

Inify Laboratories: 60% försäljningstillväxt och mycket positiv respons på expansionen till Storbritannien

Inify Laboratories: 60% quarterly sales growth and highly positive response to UK expansion

Inify Laboratories – New share capital registered

Inify Laboratories – Resolution to issue new shares in Private Placement and Subsequent Offering

Inify Laboratories - mandatory notification of trade

Inify Laboratories - mandatory notification of trade

Inify Laboratories – Final results of the Subsequent Offering

Inify Laboratories – Last day of the subscription period in the Subsequent Offering

Inify Laboratories – Commencement of subscription period for Subsequent Offering

Inify Laboratories enter into agreement with Swedish region

Inify Laboratories ingår avtal med Region Västmanland

Inify Laboratories – Registration of prospectus and upcoming launch of Subsequent Offering

Inify Laboratories - mandatory notification of trade

Inify Laboratories: Key information regarding potential Subsequent Offering

Inify Laboratories announces successful placement of fully guaranteed private placement

Inify Laboratories announces application periods for fully guaranteed private placement and fully guaranteed subsequent repair issue

Inify Laboratories AB (publ) - Kommuniké från extra bolagsstämma

Inify Laboratories AB (publ) - Bulletin from the extraordinary general meeting

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of SEK 150 million

Inify Laboratories - notice of Extraordinary General Meeting on December 6, 2024

Inify Laboratories – kallelse till extra bolagsstämma 6 december 2024

Inify Laboratories: Establishment in the United Kingdom and expansion into gastrointestinal diagnostics

Inify Laboratories: Etablering i Storbritannien och expansion inom mag-tarmdiagnostik

INIFY Laboratories: 62% revenue growth and strong international interest

INIFY Laboratories: 62% omsättningstillväxt och starkt internationellt intresse

Inify Laboratories AB (publ) – summary of Annual General Meeting

Inify Laboratories AB (publ) – kommuniké från årsstämma

Inify Laboratories - More diagnoses delivered in the first quarter than in the whole of 2023

Inify Laboratories - Fler diagnoser levererade under första kvartalet än under hela 2023

Inify Laboratories - Årsredovisning 2023

Inify Laboratories – notice of Annual General Meeting on May 14, 2024

Inify Laboratories – kallelse till årsstämma den 14 maj 2024

Inify Laboratories - Annual Report 2023

Förutser en märkbar ökning av kunder, volym och försäljning under 2024

Foresees a noticeable increase of customers, volume, and sales in 2024

Inify Laboratories erhåller ackreditering som medicinskt laboratorium

Inify Laboratories receives accreditation as a medical laboratory

Kontinuerlig diagnostikverksamhet och mycket positiv kundrespons

Continuous diagnostic operation and very positive feedback from customers

Inify Laboratories - Lyckad laboratorielansering under Q2 med leverans av första prostatacancerdiagnoserna

Inify Laboratories - Successful laboratory launch in Q2 with delivery of first prostate cancer diagnosis

Inify Laboratories - mandatory notification of trade

Successful launch of Inify Laboratories’ services, with first patient cases diagnosed

Framgångsrik lansering av Inify Laboratories tjänster – första patientfallen har diagnostiserats